aDivision of Infectious Diseases and International Health, Duke Global Health Institute, Duke University Medical Center, Durham bDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina cLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Curr Opin Hematol. 2014 May;21(3):193-200. doi: 10.1097/MOH.0000000000000039.
Multiple red cell variants are known to confer protection from malaria. Here, we review advances in identifying new variants that modulate malaria risk and in defining molecular mechanisms that mediate malaria protection.
New red cell variants, including an innate variant in the red cell's major Ca²⁺ pump and the acquired state of iron deficiency, have been associated with protection from clinical falciparum malaria. The polymorphisms hemoglobin C (HbC) and hemoglobin S (HbS) - known to protect carriers from severe falciparum malaria - enhance parasite passage to mosquitoes and may promote malaria transmission. At the molecular level, substantial advances have been made in understanding the impact of HbS and HbC upon the interactions between host microRNAs and Plasmodium falciparum protein translation; remodeling of red cell cytoskeletal components and transport of parasite proteins to the red cell surface; and chronic activation of the human innate immune system, which induces tolerance to blood-stage parasites. Several polymorphisms have now been associated with protection from clinical vivax malaria or reduced Plasmodium vivax density, including Southeast Asian ovalocytosis and two common forms of glucose-6-phosphate dehydrogenase deficiency.
Red cell variants that modulate malaria risk can serve as models to identify clinically relevant mechanisms of pathogenesis, and thus define parasite and host targets for next-generation therapies.
综述目的:多种红细胞变异体被认为可以预防疟疾。在此,我们综述了鉴定新的红细胞变异体的进展,这些变异体可以调节疟疾风险,并定义介导疟疾保护的分子机制。
最近的发现:新的红细胞变异体,包括红细胞主要钙泵的先天变异和缺铁的获得状态,与预防恶性疟原虫疟疾有关。已知携带血红蛋白 C (HbC) 和血红蛋白 S (HbS) 的多态性可保护携带者免受严重恶性疟原虫感染 - 增强寄生虫向蚊子的传递,并可能促进疟疾传播。在分子水平上,在理解 HbS 和 HbC 对宿主 microRNAs 与恶性疟原虫蛋白翻译之间相互作用的影响、红细胞骨架成分的重塑和寄生虫蛋白向红细胞表面的转运以及慢性激活人体天然免疫系统方面取得了重大进展,后者诱导对血液期寄生虫的耐受。现在已经发现了几种与预防临床间日疟或降低间日疟原虫密度相关的红细胞变异体,包括东南亚卵形红细胞增多症和两种常见形式的葡萄糖-6-磷酸脱氢酶缺乏症。
总结:调节疟疾风险的红细胞变异体可以作为识别发病机制中临床相关机制的模型,从而定义寄生虫和宿主的新一代治疗靶点。